NHS England Tackles Barriers To Use Of Cannabis-Based Medicines
Executive Summary
A review of barriers to the prescribing of cannabis-based medicines for children with epilepsy in England suggests that much needs to be done to generate the necessary evidence to assuage prescribers’ concerns.
You may also be interested in...
UK’s NICE Not Convinced By Cannabis-Based Medicines
New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.
UK Pilot To Generate Real World Data On Medicinal Cannabis Use
Drug Science, a UK charity, is about to launch a 20,000-patient pilot project looking at the use of medicinal cannabis for conditions like chronic pain, multiple sclerosis and Tourette’s syndrome. It says a special licensing status for such products could eventually be possible.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.